John Patrick Shannon Jr - Nov 11, 2021 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
President and Chief Operating Officer
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Stock symbol
XERS
Transactions as of
Nov 11, 2021
Transactions value $
$209,500
Form type
4
Date filed
11/12/2021, 04:12 PM
Previous filing
Oct 5, 2021
Next filing
Jan 5, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Purchase $83.5K +40K +15.16% $2.09 304K Nov 11, 2021 Direct F1
transaction XERS Common Stock Purchase $126K +60K +19.75% $2.10 364K Nov 12, 2021 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.08 to $2.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2 The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.09 to $2.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Remarks:

President and Chief Operating Officer